Accord: L'acquisition d'UDENYCA renforce sa position mondiale

Deal News | Aug 07, 2025 | PR Newswire Cision Accord Healthcare

Intas Pharmaceuticals, par l'intermédiaire de sa filiale Accord BioPharma, a acquis UDENYCA (pegfilgrastim-cbqv) de Coherus BioSciences, consolidant son statut de leader mondial dans le secteur des biosimilaires pegfilgrastim. Déjà pionnier sur le marché européen avec le premier biosimilaire de pegfilgrastim et un auto-injecteur innovant, Accord BioPharma entend accroître son influence sur le marché américain. L'acquisition inclut la transition d'employés clés de Coherus, renforçant ainsi les capacités de vente et de marketing d'Accord. Cette transaction permet à Accord d'offrir des options de traitement variées aux patients, et témoigne de l'engagement d'Intas à rendre les traitements de haute qualité plus accessibles à l'échelle mondiale.

Sectors

  • Pharmaceuticals
  • Biotechnology
  • Healthcare

Geography

  • India – Intas Pharmaceuticals is based in India, and the acquisition is expected to bolster its global market presence.
  • United States – Accord BioPharma, the U.S. division of Intas Pharmaceuticals, will distribute UDENYCA in the U.S., marking a significant expansion in this geography.
  • Europe – Accord is a leader in the European pegfilgrastim market, and the acquisition aims to strengthen its position further in this region.

Industry

  • Pharmaceuticals – The article is centered on the pharmaceutical industry, focusing on the acquisition of a key drug, UDENYCA, which is part of the biosimilar market.
  • Biotechnology – The involved companies, Intas and Coherus BioSciences, are engaged in the development and commercialization of biosimilars, emphasizing their roles in the biotechnology sector.
  • Healthcare – The acquisition impacts the healthcare sector by potentially increasing access to biosimilar treatments and enhancing patient care options.

Financials

    Participants

    NameRoleTypeDescription
    Intas PharmaceuticalsAcquirer Parent CompanyCompanyA leading pharmaceutical company engaged in the acquisition to strengthen its biosimilar portfolio.
    Coherus BioSciences, Inc.SellerCompanyA biopharmaceutical company that sold UDENYCA, with key employees transitioning to Accord BioPharma.
    Accord BioPharmaAcquirer Operating CompanyCompanyThe U.S. subsidiary of Intas Pharmaceuticals, tasked with expanding the reach of UDENYCA in the U.S. market.
    Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.Legal AdvisorCompanyProvided legal advisory services for Intas Pharmaceuticals and Accord in the acquisition transaction.